Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
TriSalus Life Sciences ( (TLSI) ) has provided an announcement.
On August 25, 2025, TriSalus Life Sciences, Inc. approved an increase in the annual compensation of their Chief Financial Officer, Mr. David Patience, from $450,000 to $550,000. Additionally, on August 28, 2025, the company granted Mr. Patience stock options to purchase 249,899 shares of common stock, contingent upon the company achieving or exceeding $75 million in revenue over a twelve-month period before the end of 2027.
The most recent analyst rating on (TLSI) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on TriSalus Life Sciences stock, see the TLSI Stock Forecast page.
Spark’s Take on TLSI Stock
According to Spark, TipRanks’ AI Analyst, TLSI is a Neutral.
The overall stock score is primarily influenced by financial performance challenges, including negative equity and cash flow issues. While there are positive aspects such as revenue growth and strategic corporate events, the financial instability and unattractive valuation weigh heavily on the score.
To see Spark’s full report on TLSI stock, click here.
More about TriSalus Life Sciences
Average Trading Volume: 101,834
Technical Sentiment Signal: Sell
Current Market Cap: $254.8M
For a thorough assessment of TLSI stock, go to TipRanks’ Stock Analysis page.